background
correct
manag
immunocompromis
patient
pneumonia
debat
evalu
preval
risk
factor
characterist
immunocompromis
patient
come
commun
pneumonia
method
conduct
secondari
analysi
intern
multicent
studi
enrol
adult
patient
come
commun
pneumonia
hospit
hospit
countri
worldwid
risk
factor
immunocompromis
includ
aid
aplast
anemia
asplenia
hematolog
cancer
chemotherapi
neutropenia
biolog
drug
use
lung
transplant
chronic
steroid
use
solid
tumor
result
least
risk
factor
immunocompromis
record
patient
enrol
preval
risk
factor
significantli
differ
across
contin
countri
chronic
steroid
use
hematolog
cancer
chemotherapi
common
among
immunocompromis
patient
communityacquir
pneumonia
cap
pathogen
frequent
identifi
preval
differ
immunocompet
patient
risk
factor
immunocompromis
independ
associ
neither
pseudomona
aeruginosa
noncommunityacquir
bacteria
specif
risk
factor
independ
associ
fungal
infect
odd
ratio
aid
hematolog
cancer
respect
p
mycobacteri
infect
aid
p
viral
infect
influenza
hematolog
cancer
p
conclus
find
could
consid
clinician
prescrib
empir
antibiot
therapi
cap
immunocompromis
patient
patient
aid
hematolog
cancer
admit
cap
may
higher
preval
fungi
mycobacteria
noninfluenza
virus
initi
evalu
patient
come
commun
pneumonia
identif
possibl
risk
factor
multidrugresist
organ
unusu
pathogen
crucial
microbiolog
identif
found
hospit
patient
pneumonia
come
commun
usual
requir
hour
avail
patient
treat
empir
delay
initi
appropri
empir
antibiot
therapi
known
risk
factor
wors
clinic
outcom
therefor
relev
promptli
recogn
patient
risk
specif
pathogen
special
multidrugresist
atyp
microb
age
popul
advanc
therapeut
protocol
led
increas
preval
chronic
diseas
well
longterm
treatment
immunosuppress
agent
thu
among
patient
pneumonia
come
commun
admit
hospit
number
might
fulli
immunocompet
constantli
increas
nevertheless
real
preval
immunocompromis
among
patient
pneumonia
come
commun
still
unknown
moreov
guidelin
communityacquir
hospitalacquir
pneumonia
address
topicwhat
specif
exclud
patient
clinic
characterist
determin
immunocompromis
current
evid
literatur
also
scarc
knowledg
studi
address
clinic
evalu
initi
empir
antibiot
coverag
patient
come
commun
pneumonia
immunocompromis
moreov
specif
risk
factor
assess
caus
microbiolog
help
clinician
choos
appropri
manag
patient
clearli
identifi
thu
aim
current
studi
identifi
preval
type
microbiolog
intercorrel
differ
risk
factor
immunocompromis
hospit
patient
pneumonia
come
commun
secondari
analysi
global
initi
mrsa
pneumonia
glimp
databas
glimp
studi
intern
multicent
observ
pointpreval
studi
adult
patient
hospit
communityonset
pneumonia
countri
worldwid
patient
enrol
singl
day
month
march
april
may
june
method
glimp
studi
publish
elsewher
coordin
center
univers
texa
health
scienc
center
san
antonio
receiv
approv
institut
review
board
adult
patient
age
year
old
come
commun
hospit
pneumonia
studi
period
includ
pneumonia
defin
presenc
new
pulmonari
infiltr
chest
radiograph
time
hospit
associ
follow
criteria
new
increas
cough
withwithout
sputum
product
andor
purul
respiratori
secret
fever
hypothermia
evid
system
inflamm
ie
abnorm
white
blood
cell
count
increas
creactiv
protein
procalcitonin
level
hospit
patient
diagnosi
hospitalacquir
ventilatorassoci
pneumonia
exclud
data
collect
medic
record
time
hospit
admiss
data
gather
includ
demograph
respiratori
cardiovascular
comorbid
condit
immunocompromis
statu
chronic
medic
condit
sever
pneumonia
defin
either
intens
care
unit
admiss
use
invas
noninvas
mechan
ventil
use
vasopressorsinotrop
first
hour
hospit
admiss
specif
risk
factor
resist
pathogen
infect
includ
chronic
aspir
bedridden
malnutrit
presenc
enter
tube
feed
indwel
cathet
includ
central
venou
urinari
cathet
previou
infect
chronic
microbi
colon
previou
healthcar
exposur
number
type
microbiolog
sampl
obtain
within
hour
hospit
admiss
also
collect
cultureposit
test
kind
sampl
antibiot
resist
pattern
also
gather
along
empir
antibiot
treatment
given
within
hour
hospit
admiss
diagnost
test
perform
accord
local
standard
oper
procedur
includ
collect
respiratori
blood
cultur
test
urinari
antigen
microbiolog
examin
suscept
test
perform
accord
local
standard
protocol
within
first
hour
hospit
admiss
multivari
logist
regress
model
perform
patient
posit
cultur
identifi
specif
risk
factor
singl
pathogen
caus
pathogen
stratifi
accord
coverag
standard
therapi
communityacquir
pneumonia
cap
cover
standard
cap
therapi
includ
follow
noncommunityacquir
bacteria
acinetobact
baumanii
enterococcu
vancomycinresist
nocardia
spp
mycobacteria
fungi
aspergillu
fumigatu
coccidioid
criptococcu
pneumocysti
jirovecii
virus
influenza
cover
standard
cap
therapi
includ
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
methicillinsensit
aureu
enterobact
spp
enterococcu
spp
escherichia
coli
haemophilu
influenza
klebsiella
pneumonia
moraxella
catarrhali
proteu
mirabili
serratia
marcescen
streptococcu
pneumonia
chlamydia
pneumonia
mycoplasma
pneumonia
legionella
pneumophilia
anaerob
bacteria
influenza
virus
atyp
pathogen
includ
c
pneumonia
pneumonia
l
pneumophilia
cap
therapi
defin
ceftriaxon
ampicillinsulbactam
amoxicillinclavulan
cefepim
ceftazidim
piperacillintazobactam
plu
macrolid
fluoroquinolon
alon
eventu
associ
vancomycin
linezolid
oseltamivir
immunocompromis
defin
presenc
follow
risk
factor
aid
defin
either
human
immunodefici
viru
infect
lymphocyt
count
occurr
aidsdefin
condit
aplast
anemia
asplenia
hematolog
cancer
defin
lymphoma
acut
chronic
leukemia
multipl
myeloma
chemotherapi
last
month
neutropenia
defin
neutrophil
count
complet
blood
cell
count
biolog
drug
use
includ
trastuzumab
therapi
autoimmun
diseas
eg
antitumor
necrosi
factor
prescrib
month
hospit
admiss
lung
transplant
chronic
steroid
use
mgd
prednison
equival
month
hospit
admiss
lung
cancer
either
neutropenia
chemotherapi
solid
tumor
either
neutropenia
chemotherapi
immunocompromis
immunocompromis
state
includ
congenitalgenet
immunocompromis
immunosuppress
therapi
due
hematolog
cancer
solid
organ
transplant
lung
two
studi
group
identifi
versu
without
risk
factor
immunocompromis
categor
variabl
express
count
percentag
compar
use
test
continu
variabl
compar
use
unpair
student
test
mannwhitney
download
http
auckland
univers
technolog
user
januari
test
appropri
statist
signific
defin
p
network
analysi
conduct
repres
frequenc
immunocompromis
variabl
relationship
size
circl
circl
visibl
figur
network
analysi
repres
singl
risk
factor
immunocompromis
repres
preval
risk
factor
strength
associ
variabl
predict
valu
variabl
categor
quartil
analyz
use
univari
regress
logist
analysi
multivari
model
obtain
use
cox
regress
analysi
identifi
independ
predictor
specif
pathogen
use
entri
level
p
valu
remov
level
p
valu
hazard
ratio
adjust
analys
obtain
statist
analys
perform
ibm
spss
softwar
version
statist
mac
version
ibm
crop
stata
softwar
statacorp
among
patient
enrol
glimp
databas
risk
factor
immunocompromis
identifi
preval
patient
pneumonia
come
commun
risk
factor
immunocompromis
differ
among
contin
countri
depict
figur
supplementari
tabl
preval
immunocompromis
significantli
higher
north
south
america
rest
world
vs
p
vs
p
respect
supplementari
tabl
figur
distribut
preval
immunocompromis
among
differ
countri
particip
studi
categor
data
total
case
preval
risk
factor
immunocompromis
depict
figur
chronic
steroid
use
hematolog
cancer
chemotherapi
frequent
one
total
patient
risk
factor
immunocompromis
figur
result
network
analysi
risk
factor
immunocompromis
depict
figur
relationship
identifi
chemotherapi
solid
tumor
lung
cancer
hematolog
cancer
chronic
steroid
use
immunocompromis
chronic
steroid
use
clinic
featur
diseas
sever
immunocompet
versu
immunocompromis
patient
shown
tabl
supplementari
tabl
immunocompromis
patient
significantli
younger
malnourish
higher
frequenc
comorbid
condit
previou
infect
colon
resist
pathogen
frequent
contact
healthcar
system
preval
sever
pneumonia
differ
among
studi
group
microbiolog
test
perform
immunocompromis
immunocompet
patient
p
bacteremia
found
immunocompromis
p
immunocompet
patient
least
posit
cultur
obtain
immunocompromis
immunocompet
patient
p
microbiolog
find
provid
tabl
differ
sever
diseas
found
see
supplementari
tabl
main
find
present
studi
follow
patient
admit
pneumonia
commun
risk
factor
immunocompromis
signific
differ
among
contin
countri
rang
contin
countri
chronic
steroid
use
far
preval
risk
factor
lead
immunocompromis
follow
hematolog
cancer
chemotherapi
immunocompromis
patient
overlap
risk
factor
also
associ
one
anoth
differ
way
risk
factor
immunocompromis
independ
associ
specif
pathogen
aid
ie
fungal
mycobacteri
infect
hematolog
cancer
ie
fungal
infect
viral
infect
influenza
almost
hospit
patient
cap
immunocompet
therefor
mandatori
provid
clinician
recommend
guidelin
manag
hospit
patient
pneumonia
come
commun
risk
factor
immunocompromis
current
guidelin
assess
pneumonia
immunocompromis
patient
come
commun
random
control
trial
rct
observ
prospect
studi
miss
owe
fact
gener
studi
assess
manag
strategi
pneumonia
exclud
immunocompromis
patient
take
account
singl
specif
risk
factor
lack
inform
immunocompromis
could
lead
underestim
real
preval
higher
rate
treatment
failur
overestim
overus
widespectrum
antibiot
found
global
preval
immunocompromis
among
patient
come
commun
pneumonia
significantli
higher
frequenc
south
north
america
variabl
among
contin
countri
probabl
attribut
differ
healthcar
system
rate
hospit
immunocompromis
patient
analysi
show
frequent
risk
factor
immunocompromis
chronic
use
system
steroid
age
popul
therapeut
advanc
favor
increas
burden
chronic
diseas
longterm
therapi
immunosuppress
agent
particular
steroid
agent
frequent
prescrib
wide
spectrum
efficaci
sever
diseas
therefor
mani
patient
present
emerg
room
pneumonia
receiv
chronic
steroid
treatment
data
avail
popul
group
studi
need
character
patient
provid
individu
manag
hematolog
cancer
chemotherapi
lead
immunocompromis
factor
find
consist
previou
studi
patient
recruit
observ
studi
includ
patient
solid
hematolog
cancer
underw
chemotherapi
associ
neutropenia
dedic
guidelin
recommend
avail
especi
respiratori
virus
fungi
p
jirovecii
network
analysi
show
sever
risk
factor
immunocompromis
show
associ
especi
chemotherapi
associ
hematolog
cancer
solid
tumor
immunocompromis
associ
chronic
steroid
use
moreov
neutropen
patient
well
repres
mainli
affect
also
hematolog
cancer
treatment
chemotherapi
result
suggest
patient
may
risk
factor
characterist
clinic
assess
comprehens
take
consider
risk
factor
immunocompromis
associ
biolog
mechan
contrast
aid
lung
transplant
asplenia
aplast
anemia
seem
less
frequent
admiss
repres
distinct
clinic
entiti
find
previou
studi
seem
line
result
aid
patient
consid
distinct
patient
popul
observ
studi
avail
asplenia
aplast
anemia
agreement
previou
report
pneumonia
lead
microorgan
immunocompromis
immunocompet
group
among
pathogen
cover
standard
cap
therapi
p
aeruginosa
frequent
isol
immunocompromis
compar
immunocompet
patient
find
differ
microbiolog
result
previou
studi
gramposit
bacteria
especi
aureu
frequent
identifi
patient
immunocompromis
differ
caus
li
coauthor
found
patient
immunolog
disord
treat
system
steroid
cytotox
agent
higher
incid
infect
caus
gramneg
bacteria
mainli
p
aeruginosa
similar
find
could
explain
preval
patient
expos
chronic
steroid
cohort
among
pathogen
cover
standard
cap
therapi
immunocompromis
patient
frequent
infect
nocardia
spp
ntm
p
jirovecii
fumigatu
virus
influenza
infect
p
jirovecii
ntm
frequent
identifi
patient
aid
p
jirovecii
also
frequent
type
immunocompromis
solid
hematolog
cancer
patient
underw
chemotherapi
fungal
infect
eg
candida
spp
fumigatu
highli
incid
neutropen
hematolog
cancer
patient
viral
infect
influenza
especi
respiratori
syncyti
viru
frequent
patient
underw
hematopoiet
stem
cell
lung
transplant
convers
nocardia
spp
infect
mainli
describ
solid
organ
transplant
recipi
result
consist
previou
find
suggest
need
indepth
microbiolog
workup
includ
communityacquir
pathogen
microorgan
cover
standard
therapi
surprisingli
found
risk
factor
immunocompromis
independ
associ
p
aeruginosa
noncommunityacquir
bacteria
contrast
aid
hematolog
cancer
associ
fungal
mycobacteri
noninfluenza
viral
pneumonia
respect
empir
therapi
includ
p
aeruginosa
coverag
highli
preval
immunocompromis
patient
contrari
particular
attent
given
fungal
mycobacteri
viral
caus
patient
admit
aid
hematolog
cancer
final
bacteremia
rate
differ
studi
group
knowledg
studi
bacteremia
immunocompromis
gener
major
studi
focus
bacteremia
hematopoiet
stem
cell
transplant
preval
vari
depend
type
bacteria
hostrel
factor
studi
address
topic
kidney
transplant
recipi
report
preval
bacteremia
rang
final
studi
address
hiv
bacteremia
preval
rang
depend
pathogen
grade
immunosuppress
preval
bacteremia
studi
immunocompet
immunocompromis
patient
differ
preval
bacteremia
due
mainli
differ
risk
factor
immunocompromis
studi
chronic
steroid
use
hematolog
cancer
chemotherapi
previous
report
literatur
current
studi
limit
strength
first
knowledg
first
studi
show
worldwid
perspect
immunocompromis
among
patient
come
commun
pneumonia
larg
divers
sampl
patient
enrol
across
differ
countri
contin
howev
abl
involv
mani
investig
asia
africa
case
occur
north
america
europ
thu
limit
generaliz
find
anoth
major
limit
unfeas
grade
sever
immunocompromis
therefor
stratifi
patient
defin
physiopatholog
interact
differ
risk
factor
especi
regard
use
biolog
drug
chronic
steroid
furthermor
potenti
import
risk
factor
immunocompromis
state
solid
organ
transplant
lung
specif
investig
final
outcom
data
collect
strongli
limit
specul
correct
empir
antibiot
therapi
use
immunocompromis
patient
cap
conclus
studi
offer
scientif
commun
perspect
immunocompromis
patient
come
commun
pneumonia
futur
prospect
studi
patient
specif
risk
factor
immunocompromis
could
provid
practic
recommend
particular
crucial
prepar
guidelin
certain
preval
popul
group
patient
expos
chronic
steroid
hematolog
cancer
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
author
contribut
f
p
g
r
particip
studi
design
analysi
data
write
manuscript
take
respons
integr
work
g
r
l
f
r
j
r
j
g
c
f
b
critic
review
final
manuscript
